NASHUA, N.H., Feb. 4 /PRNewswire-FirstCall/ -- iCAD, Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that the Company tops the Mammography CAD market in user satisfaction, according to the independent healthcare research group MD Buyline.
In its 2007 User Satisfaction Report, MD Buyline ranked iCAD #1 in mammography CAD user satisfaction including the company’s system performance, system reliability, service response time, applications training, service repair quality, and installation/implementation capabilities as compared to Hologic/R2. In fact, iCAD outperformed its leading competitor in all six of these categories for eight consecutive quarters.
“We are extremely pleased to have achieved the #1 position in MD Buyline’s User Satisfaction report,” said Ken Ferry, President and CEO of iCAD, Inc. “iCAD is not only 100 percent committed to delivering superior CAD solutions that help radiologists detect the hardest to find cancers earlier, we have also made significant investments in post-sales customer support. We thank iCAD users for affirming that these investments have resulted in industry- leading customer training and product implementation, support response time, and overall service quality.”
About MD Buyline
MD Buyline provides the most comprehensive database of information on healthcare products. Their data assists healthcare providers through every phase of the purchasing process from researching Emerging Technologies to final negotiations. MD Buyline members use the data to make informed decisions, which enables cost savings and operational efficiencies. For MDBuyline, contact Rod Faulkner, analyst at 214-891-6796 or via e-mail at rod.faulkner@mdbuyline.com
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over 1800 women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com.
For iCAD, contact Darlene Deptula-Hicks, EVP and CFO at 603-882-5200 x7944 or via email at ddeptula@icadmed.com
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at icad@lhai.com
For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
CONTACT: Darlene Deptula-Hicks, EVP and CFO of iCAD, Inc.,
+1-603-882-5200, ext. 7944, ddeptula@icadmed.com; For iCAD Investor
Relations, Anne Marie Fields of Lippert-Heilshorn & Associates,
+1-212-838-3777, ext. 6604, icad@lhai.com; or For iCAD Public Relations,
Wendy Ryan of Schwartz Communications, +1-781-684-0770,
icad@schwartz-pr.com
Web site: http://www.icadmed.com/
